

Wrightington, Wigan and Leigh Teaching Hospitals

NHS Foundation Trust

Information Governance Department

Suite 9
Buckingham Row
Brick Kiln Lane
Wigan
WN1 1XX

Email: foi@wwl.nhs.uk

Web: www.wwl.nhs.uk

Ref: FOI/2025/10788

Date Received: 28th May 2025

Response Due: 25th June 2025

Date: 30th May 2025

Dear Sir/Madam

With reference to your request for information received on 28th May 2025, I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do hold the information you have requested. A response to each part of your request is provided below.

In your request you asked:

I would like to submit an FOI request for the following data for Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust:

- 1. The number of patients treated for Dravet syndrome in 2024, ideally separated by month, or quarter**
 - a. Patient numbers segmented by age:**
 - i. 0-3 years old
 - ii. 4-8 years old
 - iii. 9-18 years old
 - iv. 18 years+
- 2. The number of patients treated for Dravet syndrome in 2025, ideally separated by month, or quarter**
 - a. Patient numbers segmented by age:**
 - i. 0-3 years old
 - ii. 4-8 years old
 - iii. 9-18 years old
 - iv. 18 years+
- 3. The number of patients treated for Lennox-Gastaut syndrome in 2024, ideally separated by month, or quarter**
 - a. Patient numbers segmented by age:**
 - i. 0-3 years old

- ii. 4-8 years old
 - iii. 9-18 years old
 - iv. 18 years+
- 4. The number of patients treated for Lennox-Gastaut syndrome in 2025, ideally separated by month, or quarter
 - a. Patient numbers segmented by age:
 - i. 0-3 years old
 - ii. 4-8 years old
 - iii. 9-18 years old
 - iv. 18 years+
- 5. The above data separated by treatment, focusing on the following treatments:
 - a. fenfluramine
 - b. sodium valproate
 - c. stiripentol
 - d. clobazam
 - e. cannabidiol
 - f. levetiracetam
 - g. topiramate
 - h. potassium bromide
 - i. Other treatments
 - i. carbamazepine
 - ii. gabapentin
 - iii. lacosamide
 - iv. lamotrigine
 - v. oxcarbazepine
 - vi. phenobarbital
 - vii. pregabalin
 - viii. tiagabine
 - ix. vigabatrin
 - x. rufinamide
- 6. Numbers of patients moving from one specific treatment to another e.g. fenfluramide gains from cannabidiol, sodium valproate losses to cannabidiol
- 7. Alternatively, just the numbers of patients on each treatment for each month/quarter will be able to show how the numbers on each treatment are changing

Please redirect your questions to Northern Care Alliance NHS Foundation Trust (adults) and Manchester University NHS Foundation Trust (paediatrics) at FreedomofInformationRequests@nca.nhs.uk and foi@mft.nhs.uk

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 40 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Masterman', with a horizontal line extending from the end.

Gary Masterman
Associate Director of Pharmacy (Governance Assurance)

PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire, SK9 5AF

Helpline number: 0303 123 111